Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses: A Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: Many preschool children develop recurrent, severe episodes of lower respiratory tract illness (LRTI). Although viral infections are often present, bacteria may also contribute to illness pathogenesis. Strategies that effectively attenuate such episodes are needed. OBJECTIVE: To evaluate if early administration of azithromycin, started prior to the onset of severe LRTI symptoms, in preschool children with recurrent severe LRTIs can prevent the progression of these episodes. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled, parallel-group trial conducted across 9 academic US medical centers in the National Heart, Lung, and Blood Institute's AsthmaNet network, with enrollment starting in April 2011 and follow-up complete by December 2014. Participants were 607 children aged 12 through 71 months with histories of recurrent, severe LRTIs and minimal day-to-day impairment. INTERVENTION: Participants were randomly assigned to receive azithromycin (12 mg/kg/d for 5 days; n = 307) or matching placebo (n = 300), started early during each predefined RTI (child's signs or symptoms prior to development of LRTI), based on individualized action plans, over a 12- through 18-month period. MAIN OUTCOMES AND MEASURES: The primary outcome measure was the number of RTIs not progressing to a severe LRTI, measured at the level of the RTI, that would in clinical practice trigger the prescription of oral corticosteroids. Presence of azithromycin-resistant organisms in oropharyngeal samples, along with adverse events, were among the secondary outcome measures. RESULTS: A total of 937 treated RTIs (azithromycin group, 473; placebo group, 464) were experienced by 443 children (azithromycin group, 223; placebo group, 220), including 92 severe LRTIs (azithromycin group, 35; placebo group, 57). Azithromycin significantly reduced the risk of progressing to severe LRTI relative to placebo (hazard ratio, 0.64 [95% CI, 0.41-0.98], P = .04; absolute risk for first RTI: 0.05 for azithromycin, 0.08 for placebo; risk difference, 0.03 [95% CI, 0.00-0.06]). Induction of azithromycin-resistant organisms and adverse events were infrequently observed. CONCLUSIONS AND RELEVANCE: Among young children with histories of recurrent severe LRTIs, the use of azithromycin early during an apparent RTI compared with placebo reduced the likelihood of severe LRTI. More information is needed on the development of antibiotic-resistant pathogens with this strategy. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01272635.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Asthma and Wheezing in the First Six Years of Life
Martinez, F. D., Wright, A. L., Taussig, L. M., Holberg, C. J., Halonen, M., & Morgan, W. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199501193320301 · Cited by 3,823
Self-citationSurvival Analysis, Techniques for Censored and Truncated Data
Rao, M. B. (1998) · Technometrics · doi:10.1080/00401706.1998.10485206 · Cited by 3,617
Guidelines for the diagnosis and management of asthma.
Solomon, P. A. (1992) · PubMed · Cited by 2,004
Costelloe, C., Metcalfe, C., Lovering, A., Mant, D., & Hay, A. D. (2010) · BMJ · doi:10.1136/bmj.c2096 · Cited by 1,981
National surveillance for asthma--United States, 1980-2004.
Moorman, J. E., Rudd, R. A., Johnson, C. A., King, M., Minor, P., Bailey, C., Scalia, M. R., & Akinbami, L. J. (2007) · PubMed · Cited by 1,340
Wheezing Rhinovirus Illnesses in Early Life Predict Asthma Development in High-Risk Children
Jackson, D. J., Gangnon, R. E., Evans, M. D., Roberg, K. A., Anderson, E. L., Pappas, T. E., Printz, M. C., Lee, W.-M., Shult, P. A., Reisdorf, E., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200802-309oc · Cited by 1,317
Self-citationLong-Term Inhaled Corticosteroids in Preschool Children at High Risk for Asthma
Guilbert, T. W., Morgan, W. J., Zeiger, R. S., Mauger, D. T., Boehmer, S. J., Szefler, S. J., Bacharier, L. B., Lemanske, R. F., Strunk, R. C., Allen, D. B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051378 · Cited by 1,054
Self-citationRhinovirus illnesses during infancy predict subsequent childhood wheezing
Lemanske, R. F., Jackson, D. J., Gangnon, R. E., Evans, M. D., Li, Z., Shult, P. A., Kirk, C. J., Reisdorf, E., Roberg, K. A., Anderson, E. L., et al. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.06.024 · Cited by 735 · cited 3×
“Parents or guardians were instructed to call the clinical center if any of the following levels of symptoms that represented a severe LRTI occurred: (1) having symptoms that were more than mild after 3 albuterol administrations over 1 hour, (2) requiring albuterol administrations more often than once every 4 hours, (3…”
Self-citationThe role of chemokines in neutrophil biology
Kobayashi, Y. (2008) · Frontiers in Bioscience · doi:10.2741/2853 · Cited by 545
Hull, J. (2000) · Thorax · doi:10.1136/thorax.55.12.1023 · Cited by 515
Cited by
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288
RetractedMycoplasma pneumoniae from the Respiratory Tract and Beyond
Waites, K. B., Xiao, L., Liu, Y., Balish, M. F., & Atkinson, T. P. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00114-16 · Cited by 884
La Scola, B., Le Bideau, M., Andreani, J., Hoang, V. T., Grimaldier, C., Colson, P., Gautret, P., & Raoult, D. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-03913-9 · Cited by 811
COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment
Parasher, A. (2021) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2020-138577 · Cited by 776
An Update on Current Therapeutic Drugs Treating COVID-19
Wu, R., Wang, L., Kuo, H.-C. D., Shannar, A., Peter, R., Chou, P. J., Li, S., Hudlikar, R., Liu, X., Liu, Z., et al. (2020) · Current Pharmacology Reports · doi:10.1007/s40495-020-00216-7 · Cited by 599
Boopathi, S., Poma, A. B., & Kolandaivel, P. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1758788 · Cited by 529
Treatment options for COVID-19: The reality and challenges
Jean, S.-S., Lee, P.-I., & Hsueh, P.-R. (2020) · Journal of Microbiology, Immunology and Infection · doi:10.1016/j.jmii.2020.03.034 · Cited by 518
Florin, T. A., Plint, A. C., & Zorc, J. J. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30951-5 · Cited by 452
Immune Dysregulation in Children With Down Syndrome
Huggard, D., Doherty, D. G., & Molloy, E. J. (2020) · Frontiers in Pediatrics · doi:10.3389/fped.2020.00073 · Cited by 144
Edwards, M. R., Saglani, S., Schwarze, J., Skevaki, C., Smith, J. A., Ainsworth, B., Almond, M., Andreakos, E., Belvisi, M. G., Chung, K. F., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.02448-2016 · Cited by 55
Self-citationAltman, M. C., Beigelman, A., Ciaccio, C., Gern, J. E., Heymann, P. W., Jackson, D. J., Kennedy, J. L., Kloepfer, K., Lemanske, R. F., McWilliams, L. M., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.12.904 · Cited by 37
Self-citation
Metadata
- Authors
- Bacharier, L. B., Guilbert, T. W., Mauger, D. T., Boehmer, S., Beigelman, A., Fitzpatrick, A. M., Jackson, D. J., Baxi, S. N., Benson, M., Burnham, C.-A. D., Cabana, M., Castro, M., Chmiel, J. F., Covar, R., Daines, M., Gaffin, J. M., Gentile, D. A., Holguin, F., Israel, E., Kelly, H. W., Lazarus, S. C., Lemanske, R. F., Ly, N., Meade, K., Morgan, W., Moy, J., Olin, T., Peters, S. P., Phipatanakul, W., Pongracic, J. A., Raissy, H. H., Ross, K., Sheehan, W. J., Sorkness, C., Szefler, S. J., Teague, W. G., Thyne, S., Martinez, F. D., & for the National Heart, L.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2015-11-17
- Volume
- 314
- Issue
- 19
- Pages
- 2034
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2176892781
- Cited by
- 287
- References
- 35
- FWCI
- 14.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.